• Medientyp: E-Artikel; Sonstige Veröffentlichung
  • Titel: X-ray screening identifies active site and allosteric inhibitors of SARS-CoV-2 main protease
  • Beteiligte: Günther, Sebastian [VerfasserIn]; Reinke, Patrick Y. A. [VerfasserIn]; Fernández-García, Yaiza [VerfasserIn]; Lieske, Julia [VerfasserIn]; Lane, Thomas J. [VerfasserIn]; Ginn, Helen M. [VerfasserIn]; Koua, Faisal H. M. [VerfasserIn]; Ehrt, Christiane [VerfasserIn]; Ewert, Wiebke [VerfasserIn]; Oberthuer, Dominik [VerfasserIn]; Yefanov, Oleksandr [VerfasserIn]; Meier, Susanne [VerfasserIn]; Lorenzen, Kristina [VerfasserIn]; Krichel, Boris [VerfasserIn]; Kopicki, Janine-Denise [VerfasserIn]; Gelisio, Luca [VerfasserIn]; Brehm, Wolfgang [VerfasserIn]; Dunkel, Ilona [VerfasserIn]; Seychell, Brandon [VerfasserIn]; Gieseler, Henry [VerfasserIn]; Norton-Baker, Brenna [VerfasserIn]; Escudero-Pérez, Beatriz [VerfasserIn]; Domaracky, Martin [VerfasserIn]; Saouane, Sofiane [VerfasserIn]; [...]
  • Erschienen: Washington, DC : American Association for the Advancement of Science, 2021
  • Erschienen in: Science 372 (2021), Nr. 6542 ; Science
  • Ausgabe: published Version
  • Sprache: Englisch
  • DOI: https://doi.org/10.15488/15194; https://doi.org/10.1126/science.abf7945
  • ISSN: 0036-8075
  • Schlagwörter: Antiviral Agents ; Animals ; Chlorocebus aethiops ; Allosteric Site ; Catalytic Domain
  • Entstehung:
  • Anmerkungen: Diese Datenquelle enthält auch Bestandsnachweise, die nicht zu einem Volltext führen.
  • Beschreibung: The coronavirus disease (COVID-19) caused by SARS-CoV-2 is creating tremendous human suffering. To date, no effective drug is available to directly treat the disease. In a search for a drug against COVID-19, we have performed a high-throughput X-ray crystallographic screen of two repurposing drug libraries against the SARS-CoV-2 main protease (Mpro), which is essential for viral replication. In contrast to commonly applied X-ray fragment screening experiments with molecules of low complexity, our screen tested alreadyapproved drugs and drugs in clinical trials. From the three-dimensional protein structures, we identified 37 compounds that bind to Mpro. In subsequent cell-based viral reduction assays, one peptidomimetic and six nonpeptidic compounds showed antiviral activity at nontoxic concentrations. We identified two allosteric binding sites representing attractive targets for drug development against SARS-CoV-2.
  • Zugangsstatus: Freier Zugang